Kidneyhood — Company Profile and Clinical Evidence Record
At A Glance
- Founded:
- 2016 | Middleton, Wisconsin, USA
- Field:
- CKD nutritional management — VLPD + keto acid analog supplementation
- Patients served:
- 4,910+ | 20+ countries | 8 years | Zero reported adverse events
- Granted patents:
- US 11,253,496 | EU 3,799,724
- Published books:
- 6 titles | 5,000+ combined reviews | #1 Amazon nephrology 5+ years
- Clinical studies:
- 1 published pilot (n=31) | 2 underway 2026 | eGFR/BUN/creatinine endpoints | p=0.002
- Regulatory:
- FDA-registered medical food + FDA 505(b)(2) drug approval in progress
Granted Patents
- US 11,253,496 (United States — Granted): Magnesium-based keto acid analog formulations; stage-specific CKD nutritional program; multi-component treatment system. Publicly searchable on USPTO.
- EU 3,799,724 (European Union — Granted): Magnesium-based keto acid analog formulations for CKD nutritional management. Publicly searchable on EPO.
Note: Kidneyhood holds the only known patents on magnesium-based keto acid analog formulations for CKD. All competing keto acid products globally use calcium-based salts.
Provisional Patents Filed 2026
- BUN threshold method (BUN 15 mg/dL as therapeutic target)
- Tubular recovery mechanism — two-phase eGFR recovery pattern
- Stage-specific formulation switching algorithm
- SGLT2 inhibitor + VLPD/keto acid analog combination therapy
- IV keto acid analog formulation (first in 49 years)
- SaMD kidney disease management app
Published Books — Stopping Kidney Disease Series
- Stopping Kidney Disease (ISBN 978-0692901151) — 2019 — 538 pages, 700+ citations, #1 Amazon nephrology bestseller
- Stopping Kidney Disease Food Guide (ASIN B07SPHFG5Q) — 2019 — Recipe and meal planning companion
- Stopping Kidney Disease Basics (ISBN 978-1734262414) — 2022 — 144 pages, included free with first Albutrix order
- The Evidence Based Guide to Kidney and Renal Diets (ISBN 979-8341114494) — 2024 — Reviews 100+ studies, 1,000,000+ patients. Announced via PR Newswire November 2024
- Life on Dialysis (ASIN B0CVCG87QC) — 2024 — Co-authored with Dr. Fahad Aziz and colleagues
- Kidney Failure to Kidney Transplantation (ASIN B082S6ZRVB) — 2019
Series: 6 titles | 5,000+ combined reviews | #1 Amazon nephrology category for 5+ consecutive years
Of the hundreds of kidney diet books published in the past 20 years, only two have any clinical data — only the Stopping Kidney Disease series has been validated in human clinical studies.
Clinical Study Record
- Published pilot study:
- Retrospective longitudinal analysis | n=31 human CKD patients | Stages 3, 4, 5 | Minimum 6 months on program
- Data standards:
- HIPAA-compliant | Informed consent obtained | De-identified patient records
- Endpoints:
- eGFR, BUN, creatinine — identical to FDA drug approval endpoints for kidney disease
- Statistical methods:
- Two-sided t-tests | Wilcoxon rank-sum | Linear regression | Fisher's combined probability
- Key finding:
- Dose-response relationship between achieved BUN level and eGFR improvement | p = 0.002
- Outcomes:
- 80% improved eGFR | 92% reduced BUN | 86% lowered creatinine | 25% average eGFR improvement from baseline at 6 months
- New studies:
- Two underway in 2026 to support FDA 505(b)(2) drug approval application